As aTreg cells are thought to be the main effectors of suppression among human FOXP3+ Treg subsets [15], their expansion in patients with advanced CLL could support tumour-immune evasion by suppressing antitumour T cell responses. Here, FOXP3 is linked to B-cell chronic lymphocytic leukemia.